← FDA DRUG APPROVALS

FDA ANDA · ANDA204960

CISATRACURIUM BESYLATE PRESERVATIVE FREE

Sponsor: HENGRUI PHARMA

APPLICATION
ANDA204960
TYPE
ANDA
ORIGINAL APPROVAL
2017-01-27
LATEST ACTION
2023-02-06
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CISATRACURIUM BESYLATE PRESERVATIVE FREEDiscontinued
CISATRACURIUM BESYLATE EQ 10MG BASE/ML · INJECTABLE · INJECTION
CISATRACURIUM BESYLATEDiscontinued
CISATRACURIUM BESYLATE EQ 2MG BASE/ML · INJECTABLE · INJECTION
CISATRACURIUM BESYLATE PRESERVATIVE FREEDiscontinued
CISATRACURIUM BESYLATE EQ 2MG BASE/ML · INJECTABLE · INJECTION

Approval history

2023-02-06Labeling · Supplement 15 · standardAP
2023-02-06Labeling · Supplement 16 · standardAP
2020-07-31Labeling · Supplement 8 · standardAP
2017-01-27UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →